Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Psoriasis: KOL Insight (2016)

Product Code:
Publication Date:
June 2015

There is no shortage of effective treatments for psoriasis, and the introduction of novel anti-IL17 and anti-IL23 antibody-based therapies will further expand the treatment options. How will the market develop in the future as the new classes of drugs find their place in the treatment paradigm and which companies and products will be impacted?

Psoriasis: KOL Insight provides a business critical examination through the expert insights of 12 leading front-line US and European Key Opinion Leaders. Learn what leading clinicians think about current therapies, pipeline candidates, biosimilars and the issues that influence their prescribing decisions.

What do KOLs see as the competing strengths and weaknesses of current and pipeline therapies? What clinical advantages do the new products bring and what challenges do they face? What lessons are there for biosimilar players seeking to grow or enter this market sector? How is cost and funding influencing prescribers? Gain key insights in Psoriasis: KOL Insight.

Request Sample Pages

Key Benefits

  • Know the detailed opinions of leading front-line clinicians on current and pipeline psoriasis therapies and what they see as the critical advantages/disadvantages affecting their prescribing decisions
  • Appreciate the important factors around dosage, drug sequencing, administration, patient information and funding and identify key areas for strategic and tactical action
  • Understand what KOL’s see as the critical unmet needs in the sector
  • Drive change through better clinician and patient engagement
  • Review KOL attitudes to important clinical trials such as CLEAR, FIXTURE, ERASURE, ESTEEM and AMAGINE

Answers to Critical Questions

  • How might long clinical experience and safety data be leveraged by AbbVie to defend Humira revenues in the face of growing competition?
  • What data would KOL’s like from Novartis to strengthen their view of Cosentyx?
  • How might J&J overcome payer barriers and establish Stelara as a first line treatment choice?
  • What concerns do KOLs have about the increasing number of biosimilars entering the market and to what extent may they affect their prescribing decisions?
  • Amgen/AstraZeneca’s brodalumab, Eli Lilly’s ixekizumab and J&J guselkumab are all progressing through trials: what do see KOL’s see as their competing benefits?
  • Pricing is a contentious issue often limiting patient access – what can be done?
  • What opportunities are there for diagnostic technologies to better identify patient receptiveness to treatment?
  • What development opportunities are there for the poorly serviced mild to moderate patient group?

Report Features

  • Knowledgeable real world opinions of leading US and European KOLs on the competing advantages, disadvantages and prospects for current and pipeline psoriasis therapies
  • Treatment options mapped to plaque psoriasis patient sub groups and why particular therapy is chosen
  • Administration, dosage and safety characteristics KOLs think are the most important in terms of prescribing decisions
  • KOL views on potential impact of biosimilars on reference products
  • A review of early stage programmes for emerging approaches such as Toll-like receptors, Anti-CD162, Anti-CD4/CD25 and A3 adenosine receptor agonists

Key Opinion Leaders

KOLs from North America

  • Steven R Feldman, Professor of Dermatology, Wake Forest University Health Sciences, NC
  • Joel Gefland, Associate Professor, Department of Dermatology and Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, PA
  • Craig L. Leonardi, Clinical Professor of Dermatology, St. Louis University Medical School, MO
  • Neil Korman, Professor of Dermatology, Department of Dermatology, University Hospitals Case Medical Center, OH
  • Jeffrey Weinberg, Attending, Department of Dermatology, Mount Sinai St. Luke's Roosevelt, NY

KOLs from Europe

  • EUHervé Bachelez, Professor, Service de dermatologie I Hôpital Saint-Louis, France
  • Jonathan Barker, Professor of Dermatology, St John's Institute of Dermatology, Guys and St Thomas's Hospitals, UK
  • Giampiero Girolomoni, Department of Biomedical and Surgical Science, Section of Dermatology and Venereology, University of Verona, Italy
  • Carle Paul, Professor, Dermatology and Immunopathology, Paul Sabatier University and Larrey Hospital, 24 Chemin de Pouvourville, France
  • Lluis Puig, Department of Dermatology, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Spain
  • Anonymous KOL, Germany
  • Anonymous KOL, Germany

Request Sample Pages

Current Treatments Covered

Pipeline Therapies Covered

  • Cosentyx (secukinumab), Novartis
  • Enbrel (etanercept), Amgen/Pfizer
  • Humira (adalimumab), AbbVie
  • Otezla (apremilast), Celgene
  • Remicade (infliximab), Merck & Co./J&J
  • Remsima/Inflectra (biosimilar infliximab), Celltrion/Hospira
  • Stelara (ustekinumab), Johnson & Johnson
  • BI 65506 (anti-IL23 mAb), Boehringer Ingelheim
  • brodalumab (anti-IL17R mAb), Amgen/AstraZeneca
  • certolizumab pegol (pegylated anti-TNF Fab), UCB/Dermira
  • guselkumab (anti-IL23 mAb), Johnson & Johnson/MorphoSys
  • ixekizumab (anti-IL17A mAb), Eli Lilly
  • tofacitinib (anti-JAK3), Pfizer
  • biosimilar anti-TNFs


Update Bulletins Offer Ongoing Benefits

The world of pharma is ever changing and executives must always be up-to-date with new developments that could affect their own products, position and research. That is why FirstWord’s guarantee to keep Therapy Trends clients up to date with Update Bulletins offers a real commercial advantage.

Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with the KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update.

  • Your Therapy Trends Report purchase entitles you to receive three Update Bulletins, which are published approximately every three months for 12 months following the report's publication date, June 2015.
  • You will receive a copy of each Update Bulletin once available, which are issued each quarter after the publication date.

Therapy Trends reports deliver critical and unbiased intelligence derived from in-depth interviews with the world’s foremost thought leaders on the current and future treatment landscapes in major disease areas. Research is focused on the major battlegrounds for market share and answers critical business questions about potential product positioning and competitiveness. Through continuous monitoring and frequent re-engagement with stakeholders, the FirstWord Therapy Trends analyst team delivers quarterly updates with each report ensuring insights remain current and relevant.



All Contents Copyright © 2020 Doctor's Guide Publishing Limited All Rights Reserved